Esperion Therapeutics, Inc. - Common Stock (ESPR)

Historical Holders from Q1 2014 to Q1 2025

Symbol
ESPR on Nasdaq
CUSIP
29664W105
Type / Class
Equity / Common Stock
Shares outstanding
199M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
126M
Holdings value
$277M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
191
Number of buys
76
Number of sells
-69
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Esperion Therapeutics, Inc. - Common Stock (ESPR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WASATCH ADVISORS LP 5.5% $15.7M 10.9M WASATCH ADVISORS LP Mar 31, 2025
BB BIOTECH AG 4.9% -2% $14M -$360K 9.69M -2.51% BB Biotech AG Mar 4, 2025

Institutional Holders of Esperion Therapeutics, Inc. - Common Stock (ESPR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 531K $760K -$86.1K $1.44 18
2024 Q4 126M $277M +$4.31M $2.20 191
2024 Q3 129M $213M -$19M $1.65 183
2024 Q2 137M $304M +$17.7M $2.22 178
2024 Q1 125M $336M +$140M $2.68 151
2023 Q4 71.6M $214M -$10.2M $2.99 126
2023 Q3 77.2M $75.7M -$1.56M $0.98 120
2023 Q2 74.3M $103M -$10.5M $1.39 121
2023 Q1 80.9M $129M -$21.8M $1.59 160
2022 Q4 73.3M $457M +$38.8M $6.23 160
2022 Q3 62.3M $418M +$53.6M $6.70 140
2022 Q2 55.2M $351M +$25.2M $6.36 124
2022 Q1 51.7M $240M -$9.96M $4.64 118
2021 Q4 53.2M $266M +$96.7M $5.00 113
2021 Q3 24.6M $297M -$61.2M $12.05 135
2021 Q2 28.1M $594M -$19.2M $21.15 134
2021 Q1 28.5M $799M -$65.4M $28.05 150
2020 Q4 30.8M $801M -$1.3M $26.00 149
2020 Q3 30.5M $1.13B -$33.7M $37.17 160
2020 Q2 32M $1.64B +$123M $51.31 177
2020 Q1 29.6M $916M +$54M $31.53 152
2019 Q4 24.9M $1.48B +$46.3M $59.63 164
2019 Q3 26.9M $987M -$72.1M $36.66 143
2019 Q2 27.3M $1.27B +$246M $46.52 162
2019 Q1 25.9M $1.04B +$20.9M $40.15 154
2018 Q4 26.7M $1.23B -$65.2M $46.00 150
2018 Q3 28.1M $1.25B -$107M $44.37 149
2018 Q2 30.6M $1.2B +$137M $39.19 148
2018 Q1 26.5M $1.91B +$178M $72.33 183
2017 Q4 24M $1.58B +$28.5M $65.84 162
2017 Q3 24.1M $1.21B +$160M $50.12 148
2017 Q2 20.6M $953M +$140M $46.28 125
2017 Q1 17.5M $616M +$201M $35.31 115
2016 Q4 14.8M $185M +$1.93M $12.52 93
2016 Q3 14.3M $198M +$384K $13.85 96
2016 Q2 14.5M $144M -$26.7M $9.88 96
2016 Q1 15.6M $264M -$13.1M $16.91 101
2015 Q4 16.4M $366M -$11.9M $22.26 111
2015 Q3 16.6M $392M -$218M $23.59 123
2015 Q2 15.2M $1.24B +$184M $81.76 148
2015 Q1 12.8M $1.19B +$475M $92.60 142
2014 Q4 7.76M $314M +$168M $40.44 81
2014 Q3 3.5M $85.6M +$3.11M $24.46 48
2014 Q2 5.56M $88M +$1.16M $15.84 43
2014 Q1 3.43M $51.9M +$1M $15.12 39